drugset / Trial / NCT07174375
PCSK9 Inhibitors in Acute Ischemic Stroke Patients Undergoing Endovascular Therapy
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a prospective, multicenter, randomized controlled clinical study to evaluate the efficacy of PCSK9 inhibitor in addition to standard therapy in patients with acute ischemic stroke undergoing endovascular therapy.
Timeline
- Start
- 2025-09-15
- Primary completion
- 2027-12-15
- Completion
- 2027-12-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alirocumab | Monoclonal antibody | 150 mg | Subcutaneous |
| Subject | Evolocumab | Monoclonal antibody | 420 mg | Subcutaneous |